Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Results From the Phase 3 CheckMate 238 Trial for Stage III/IV Melanoma
Checkmate 76K & Checkmate 238 Efficacy Data | OPDIVO® (nivolumab)
Sample selection prior to pooling EORTC 18,071 and CheckMate 238 data ...
Long-Term CheckMate 238 Data Support Adjuvant Nivolumab Vs Ipilimumab ...
CheckMate 238 | PDF | Melanoma | Medical Treatments
Encouraging phase 3 CheckMate 238 data: adjuvant nivolumab in resected ...
Rapids Readouts: Phase 3 CheckMate 238 Trial | OncLive
Checkmate 76K & Checkmate 238 Safety Profile | OPDIVO® (nivolumab)
ESMO 2025: CheckMate 238 Update Reinforces Nivolumab Benefit
Ep 06: CheckMate 238 - YouTube
KEYNOTE-054 and CheckMate 238 Trial Updates
Follow-up de quatro anos do CheckMate 238 mantém superioridade de ...
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial ...
CheckMate 238: nivolumab adyuvante vs ipilimumab para melanoma ...
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection ...
7-y results from CheckMate 238: adjuvant NIVO vs IPI in resected stage ...
4-year results from CheckMate 238: adjuvant nivo vs ipi in resected ...
ESMO 2023 Insights: "CheckMate 238 Trial - Adjuvant Nivo vs. Ipi in ...
CheckMate 8HW Trial at ASCO 2025: Nivolumab Plus Ipilimumab Sets New ...
CheckMate 214 Trial Final 9-Year Results at ASCO 2025: Nivolumab Plus ...
读书报告 | CheckMate 238研究： 纳武利尤单抗对比伊匹木单抗辅助治疗可切除3/4期黑色素瘤5年随访结果-MedSci.cn
ASCO GU 2023: Extended Follow-up Results from the CheckMate 274 Trial
CheckMate 238-Studie
CheckMate 238: nivolumab versus ipilimumab in stage III melanoma ...
CheckMate 238: Nivolumab Extends Recurrence-Free Survival in Advanced ...
CheckMate 238試験の9年追跡調査結果（最終） | 柏五味歯科内科リウマチクリニックブログ
CheckMate 816 Trial: The EFS Benefit of Neoadjuvant Immunization ...
CheckMate 238, conferme importanti - OncoInfo
Checkmate 238: Nivolumab bests ipilimumab for resectable stage III or ...
CheckMate 649: Nivo+CT Improves OS vs CT in Advanced Gastroesophageal ...
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 ...
Melanoma trial updates from ASCO 2018: CheckMate 238, KEYNOTE-001/006 ...
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 ...
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent ...
Fig. S1 CheckMate 218 EAP design. a Patients may have been treated ...
Melanoma - Comentários sobre os Estudos COMBI-AD e Checkmate 238. - YouTube
Un anno di immunoterapia nel melanoma - OncoInfo
PPT - Adjuvant Therapy in Melanoma: Evidence and Current Practice ...
The Journey Through Stage III Melanoma: A Guide for Patients - Conquer ...
(PDF) A Phase III study (CheckMate 238) of adjuvant immunotherapy with ...
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage ...
Estimating Long-Term Survivorship Rates Among Patients With Resected ...
Neoadjuvant or adjuvant immunotherapy in melanoma stage iii | PPTX
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant ...
(PDF) Association of selected (immune-related) adverse events and ...
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma ...
Doniesienia z badania fazy III CheckMate-238 - leczenie adjuwantowe ...
(PDF) Adjuvant therapy with nivolumab versus ipilimumab after complete ...
DailyMed - OPDIVO QVANTIG- nivolumab and hyaluronidase-nvhy injection ...
Frontiers | Nivolumab adjuvant therapy for esophageal cancer: a review ...
1089P Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage ...
OS for nivolumab and placebo after adjusting for differences in ...
Distant metastatic site a by all stage III (a), AJCC-7 (b), (c), and ...
«Опдиво» поможет предотвратить рецидив меланомы | МОСМЕДПРЕПАРАТЫ
Impact of CheckMate-238 Results for Patients With Melanoma | Targeted ...
Nivolumab bests ipilimumab in head-to-head melanoma trial ...
Nivolumab vs Ipilimumab in Resected Stage III or IV Melanoma: 9-Year ...
CONSORT diagram. a In addition, a further 99 patients were randomly ...
옵디보, CheckMate-067, CheckMate-238 결과 발표
Malignes Melanom: Ergebnisse und Perspektiven der CheckMate-238-Studie ...
【Clinical Cancer Research】可切除的III/IV期黑色素瘤免疫辅助治疗5年随访结果更新（CheckMate-238） - 知乎
Reported adverse events per 100 treatments from the studies Combi AD ...
Opdivo (Nivolumab Injection): Uses, Dosage, Side Effects, Interactions ...
Melanoma recurrence risk stratification using Bayesian systems biology ...
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell ...
FDA Label for Opdivo Qvantig Injection, Solution Subcutaneous ...
Society of Urologic Oncology - DISEASE-FREE SURVIVAL WITH LONGER FOLLOW ...
Health-related Quality of Life with Adjuvant Nivolumab After Radical ...
Impact of CheckMate-238 Results for Patients With Melanoma - YouTube
Partitioned survival model simulating the results of the CheckMate-648 ...
ESMO 2024: Real-World Characteristics and Outcomes in Patients with ...
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first ...
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus ...
clin
